SWAMY VIVEKANANDHA COLLEGE OF PHARMACY

(Affiliated to the The Tamil Nadu Dr.MGR. Medical University, Chennai,
Approved by PCI, Accredited by NBA, New Delhi)
Elayampalayam, Tiruchengode-637 205, Namakkal (Dt), Tamil Nadu.

Prof. Dr. M. KARUNANITHI
B.Pharm., M.S., Ph.D., D.Litt.,
CHAIRMAN & SECRETARY

Department of Pharmacy Practice

Presents

ADR PULSE RADAR

(SPOT IT, STOP IT)

VMCH ADR ALERT : JANUARY 2026

'Pharmacovigilance - Passive Surveillance'

VMCH AMC CHAIRMAN : Dr. S. ARTHANAREESWARAN, M.D.,
VMCH AMC CO-ORDINATOR : Dr. R. SUBASHINI, M.Pharm., Ph.D.,
DEPUTY CO-ORDINATOR : Dr. K. JEYAPRAKASH, M.D.,
TECHNICAL ASSISTANCE : Dr. T. ANGELIN GRACE, Pharm.D.,

ADVISORY BOARD : Dr. K. KRUPANITHI, M.D.,
Dr. K. B. NIVETHANA KRUPANIDHI, M.S.,
Dr. G. MURUGANANTHAN, Principal - SVCP

PATRON : PROF. Dr. M. KARUNANITHI, B.PHARM., M.S., PH.D., D.LITT.,

SWAMY VIVEKANANDHA COLLEGE OF PHARMACY

Elayampalayam, Tiruchengode-637 205, Namakkal (Dt), Tamil Nadu.

ADR PULSE RADAR : JANUARY 2026

'Pharmacovigilance - Passive Surveillance'

VMCH ADR MONITORING CENTER : Vol.1, Issue1

INTRODUCTION

Pharmacovigilance is the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other medicine / vaccine related problem.

Medicines and vaccines undergo clinical trials, but some rare or long-term side effects only appear after widespread use in diverse populations with different health conditions.

REPORTING OF ADR

ADRs can be also reported via PvPI helpline number (18001803024) on weekdays from 9:00 am to 5:30 pm. The mobile Android application for ADR reporting has also been made available to the public.

REFERENCE

1.https://www.who.int/teams/regulation-prequalification/regulation-and-safety/pharmacovigilance

2.https://pmc.ncbi.nlm.nih.gov/articles/PMC4578206/

SWAMY VIVEKANANDHA COLLEGE OF PHARMACY

Elayampalayam, Tiruchengode-637 205, Namakkal (Dt), Tamil Nadu.

ADR PULSE RADAR : JANUARY 2026

'Pharmacovigilance - Passive Surveillance'

VMCH ADR MONITORING CENTER : Vol.1, Issue1

ADR SUMMARY

Total ADR	:	26
Most Common Types	:	Cardiovascular drugs (23%)
Serious Cases	:	NIL

ADRs INVOLVED : Cardiovascular drugs (23%), Antihypertensive drugs(19%), Antibiotics(15%), Haematinics (7%), Antiviral drugs (4%), Antidiabetic drugs(4%) Antiseizure drugs (4%),Corticosteroids(4%), PPI (4%), Opioid Analgesics (4%)



IF ANY ADR, SCAN AND REPORT HERE

E-mail Id: vmchadr@gmail.com

FDA DRUG INFORMATION

FDA Requests Removal of Suicidal Behavior and Ideation Warning from Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications

FDA's Evaluation Did Not Identify an Increased Risk of Suicidal Ideation or Behavior With the Use of GLP - 1RA Medications, a move reflected in international updates by Jan 14, 2026[1]

GOVERNMENT DRUG SAFETY

Nimesulide was banned due to its unsafe and harmfuleffect.

New Delhi:

In response to safety concerns regarding the risk of Nimesulide, the Union Health Ministry of India has banned the manufacturing, selling, and distributing of Nimesulide oral formulations that contain higher than 100 mg of Nimesulide per dose for human consumption as a precaution. This ban is now effective and was initiated as a means to safeguard public health[2]

REFERENCE

1.https://www.fda.gov/drugs/drug-safety-and availability/fda- requests-removal-suicidal-behavior-and-ideation-warning- glucagon-peptide-1-receptor-agonist-glp.

2.https://www.indiatoday.in/health/story/india-bans-highdose-nimesulide-health-risks-behind-the-decision- 2844486-2025-12-31

SWAMY VIVEKANANDHA COLLEGE OF PHARMACY

Volume : 01 Issue : 01 January 2026